Postmenopausal Vaginal Atrophy Treatment Global Market Report 2025

The postmenopausal vaginal atrophy treatment market size has grown strongly in recent years. It will grow from $2.1 billion in 2024 to $2.28 billion in 2025 at a compound annual growth rate (CAGR) of 8.6%. Growth during the historical period has been influenced by factors such as a rising prevalence of postmenopausal symptoms, heightened awareness of vaginal health and menopause-related issues, an expanding global population of aging women, increased spending on women's healthcare, and a growing shift towards non-hormonal and localized treatment approaches.

The postmenopausal vaginal atrophy treatment market size is expected to see strong growth in the next few years. It will grow to $3.13 billion in 2029 at a compound annual growth rate (CAGR) of 8.3%. Contributing to this future growth are factors such as a rising number of menopause-focused clinics and gynecological consultations, increasing preference for personalized and patient-specific therapies, enhanced backing from governmental and health-focused organizations, a growing occurrence of early menopause driven by lifestyle and medical interventions, and wider accessibility of over-the-counter and online pharmacy solutions. Prominent market trends projected for the forecast period include innovations in selective estrogen receptor modulators (SERMs), the use of digital health tools and telehealth services, new advancements in drug delivery technologies, progress in non-hormonal treatment strategies, and improvements in minimally invasive gynecological procedures.

The increasing postmenopausal population is expected to drive the growth of the postmenopausal vaginal atrophy treatment market in the coming years. This population includes women who have not had a menstrual period for 12 consecutive months, marking the end of their reproductive phase. As life expectancy rises, more women are living longer and spending additional years in the postmenopausal stage. Treatments for postmenopausal vaginal atrophy help relieve symptoms such as dryness and irritation caused by decreased estrogen levels, thereby promoting vaginal health and improving overall comfort and well-being. For example, according to the Mayo Clinic in October 2022, the number of menopausal and postmenopausal women worldwide is projected to reach 1.2 billion by 2030, with an estimated 47 million women entering this stage each year. This growing demographic is contributing significantly to the expansion of the market.

Companies operating in the postmenopausal vaginal atrophy treatment market are focusing on innovative solutions like estradiol vaginal inserts to deliver targeted symptom relief and enhance adherence to hormone therapy. These inserts are small devices placed in the vagina that release estrogen locally, aiding in the restoration of thinning vaginal tissues due to menopause. They provide effective relief from symptoms such as dryness, itching, and discomfort with minimal systemic absorption. For instance, in January 2024, Knight Therapeutics, a pharmaceutical company based in Canada, launched IMVEXXY in the Canadian market. This product is used to treat moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy associated with menopause. It delivers 4 mcg or 10 mcg of estradiol directly to vaginal tissues, supporting mucosal health and reducing pain during intercourse. IMVEXXY’s unique softgel formulation ensures fast dissolution and minimal absorption into the bloodstream, offering a convenient, applicator-free, and mess-free alternative to traditional estrogen treatments. This innovation highlights the industry's dedication to developing patient-focused therapies that meet the specific needs of postmenopausal women.

In June 2023, Cosette Pharmaceuticals, a US-based pharmaceutical firm, acquired Intrarosa from Endoceutics Inc. for an undisclosed amount. This acquisition aims to enhance Cosette’s women’s health portfolio by incorporating a differentiated, patent-protected, commercially available product for the treatment of moderate-to-severe dyspareunia due to menopause. The move reinforces Cosette’s commitment to women’s health and expands its global reach, utilizing its commercial and manufacturing expertise to maintain patient access to Intrarosa. Endoceutics Inc. is a US-based provider of treatments for postmenopausal vaginal atrophy.

Major players in the postmenopausal vaginal atrophy treatment market are Pfizer Inc., AbbVie Inc., Bayer AG, Novartis AG, Novo Nordisk A/S, Viatris Inc., Teva Pharmaceutical Industries Ltd., Perrigo Company, Shionogi & Co. Ltd., Hikma Pharmaceuticals, Amneal Pharmaceuticals LLC, Lupin Pharmaceuticals, Mayne Pharma, Upsher-Smith Laboratories, Alvogen, Ligand Pharmaceuticals Incorporated, Dare Bioscience, Millicent Pharma Limited, TherapeuticsMD, and Bionovo Inc.

North America was the largest region in the postmenopausal vaginal atrophy treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in postmenopausal vaginal atrophy treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the postmenopausal vaginal atrophy treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Postmenopausal vaginal atrophy treatment includes both medical and therapeutic methods aimed at relieving symptoms like vaginal dryness, irritation, and discomfort caused by decreased estrogen levels following menopause. The primary objective is to restore vaginal tissue health, increase moisture and elasticity, and support improved sexual and urinary function. These treatments play a crucial role in preventing complications and greatly enhancing overall quality of life.

The primary categories of postmenopausal vaginal atrophy treatments consist of estrogen-based drugs, non-estrogen-based drugs, and other alternatives. Estrogen-based therapies serve as hormone treatments for addressing menopausal symptoms, promoting reproductive wellness, treating hormone-responsive cancers, and supporting gender-affirming care. These drugs can be administered through various methods, including oral, intravaginal, and others, and are available via multiple distribution channels such as hospital pharmacies, online platforms, and retail pharmacies. The treatments are used in diverse fields including gynecology, sexual wellness, and general pharmaceuticals, and cater to various end-users such as hospitals, home care setups, specialty clinics, and more.

The postmenopausal vaginal atrophy treatment market research report is one of a series of new publications that provides detailed insights into market statistics, including the global size of the postmenopausal vaginal atrophy treatment industry, regional market shares, competitive landscape, detailed market segmentation, current trends, growth opportunities, and any additional data needed to succeed in the industry. This report offers a comprehensive overview and an in-depth evaluation of both present conditions and future prospects within the market.

The postmenopausal vaginal atrophy treatment market consists of revenues earned by entities by providing services such as medical consultation and diagnosis, hormonal therapy administration, patient education and counseling, and follow-up and monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. The postmenopausal vaginal atrophy treatment market also includes sales of vaginal gels, creams, tablets, patches, and rings. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.